• Gene deletion; HGNC; HGNC:1787; CDKN2A; Zygosity=Homozygous (PubMed=9354451; PubMed=17363583).
  
• Gene deletion; HGNC; HGNC:9588; PTEN; Zygosity=Homozygous (PubMed=17363583).
  
• Mutation; HGNC; HGNC:1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=17363583; PubMed=22383533).
  

PubMed=9354451
Marina Castellano, Pamela M. Pollock, Marilyn K. Walters, Louise E. Sparrow, Louise M. Down, Brian G. Gabrielli, Peter G. Parsons, Nicholas K. Hayward;
CDKN2A/p16 is inactivated in most melanoma cell lines.
Cancer Res. 57:4868-4875(1997)

PubMed=17363583; DOI=10.1158/0008-5472.CAN-06-4152
Mitchell S. Stark, Nicholas K. Hayward;
Genome-wide loss of heterozygosity and copy number analysis in melanoma using high-density single-nucleotide polymorphism arrays.
Cancer Res. 67:2632-2642(2007)

PubMed=17516929; DOI=10.1111/j.1600-0749.2007.00375.x
Peter Johansson, Sandra Pavey, Nicholas K. Hayward;
Confirmation of a BRAF mutation-associated gene expression signature in melanoma.
Pigment Cell Res. 20:216-221(2007)

PubMed=22383533; DOI=10.1158/1535-7163.MCT-11-0676
Ken Dutton-Regester, Darryl Irwin, Priscilla Hunt, Lauren G. Aoude, Varsha Tembe, Gulietta M. Pupo, Cathy Lanagan, Candace D. Carter, Linda O'Connor, Michael O'Rourke, Richard Anthony Scolyer ...Show all 15 authors... , Graham J. Mann, Christopher W. Schmidt, Adrian Herington, Nicholas K. Hayward; Show fewer authors
A high-throughput panel for identifying clinically relevant mutation profiles in melanoma.
Mol. Cancer Ther. 11:888-897(2012)